Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Arlene Forastiere"'
Autor:
Nabil F. Saba, Saagar Pamulapati, Bhamini Patel, Mayur Mody, Primož Strojan, Robert Takes, Antti A. Mäkitie, Oded Cohen, Pia Pace-Asciak, Jan B. Vermorken, Carol Bradford, Arlene Forastiere, Yong Teng, Andreas Wieland, Alfio Ferlito
Publikováno v:
Cancers
Cancers, 15
Cancers, 15, 7
Cancers, 15
Cancers, 15, 7
Contains fulltext : 291956.pdf (Publisher’s version ) (Open Access) Head and neck cancer (HNC) is the seventh most common malignancy, with oropharyngeal squamous cell carcinoma (OPSCC) accounting for a majority of cases in the western world. While
Autor:
Rebecca Paulus, K. Kian Ang, Jay S. Cooper, Arlene Forastiere, Andre Konski, Jean Owen, Mythreyi Bhargavan, Deborah Watkins-Bruner
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 79:436-442
Purpose The specific aim of this analysis was to evaluate the feasibility of performing a cost-effectiveness analysis using Medicare data from patients treated on a randomized Phase III clinical trial. Methods and Materials Cost data included Medicar
Publikováno v:
Cancer. 101:2222-2229
BACKGROUND The current study was conducted to identify prognostic factors and report the characteristics of long-term survivors in patients with recurrent or metastatic carcinoma of the head and neck who were treated with cisplatin-based combination
Publikováno v:
Radiation Oncology Investigations. 1:111-116
Between 1987 and 1989, 12 patients with advanced unresectable head and neck carcinoma were entered on a regimen of alternating and concurrent chemotherapy and radiotherapy. During the initial phase, cisplatin (50 mg/m2/day × 3 days) was administered
Publikováno v:
American Journal of Clinical Oncology: Cancer Clinical Trials. 24:64-66
Recurrent or metastatic squamous carcinoma of the head and neck (RMSCHN) is a modestly chemoresponsive tumor; however, currently available agents have failed to improve survival. New active agents are needed for the treatment of this disease. Topotec
Autor:
Soner, Altiok, Heather, Mezzadra, Sanjay, Jagannath, Nancy, Tsottles, Michelle A, Rudek, Nadia, Abdallah, David, Berman, Arlene, Forastiere, Michael K, Gibson
Publikováno v:
International journal of oncology. 36(1)
This study aimed to describe a short term ex vivo assay to predict response to epidermal growth factor receptor (EGFR) targeted therapy (gefitinib) in adenocarcinoma patients. Four patients with locally advanced esophageal adenocarcinoma were treated
Publikováno v:
Oncology (Williston Park, N.Y.). 23(9)
Medical oncologists have traditionally had little to offer patients with metastatic radioactive iodine-resistant thyroid cancer. The 3-year survival rate of patients with differentiated thyroid cancer is less than 50%, with little response obtained f
Autor:
Arlene, Forastiere
Publikováno v:
Clinical advances in hematologyoncology : HO. 3(4)
Autor:
Maria L, Amador, Darin, Oppenheimer, Sofia, Perea, Anirban, Maitra, George, Cusatis, George, Cusati, Christi, Iacobuzio-Donahue, Sharyn D, Baker, Raheela, Ashfaq, Chris, Takimoto, Arlene, Forastiere, Manuel, Hidalgo
Publikováno v:
Cancer research. 64(24)
This study tested the hypothesis that the number of CA single sequence repeat (CA-SSR) in the intron 1 of the epidermal growth factor receptor (egfr) gene, which affects transcription efficiency of the gene, is associated with the response to EGFR in
Publikováno v:
Cancer. 101(10)
The current study was conducted to identify prognostic factors and report the characteristics of long-term survivors in patients with recurrent or metastatic carcinoma of the head and neck who were treated with cisplatin-based combination chemotherap